17 research outputs found
Evaluation of MLH1 variants of unclear significance
Inactivating mutations in the MLH1 gene cause the cancer predisposition Lynch syndrome, but for small coding genetic variants it is mostly unclear if they are inactivating or not. Nine such MLH1 variants have been identified in South American colorectal cancer (CRC) patients (p.Tyr97Asp, p.His112Gln, p.Pro141Ala, p.Arg265Pro, p.Asn338Ser, p.Ile501del, p.Arg575Lys, p.Lys618del, p.Leu676Pro), and evidence of pathogenicity or neutrality was not available for the majority of these variants. We therefore performed biochemical laboratory testing of the variant proteins and compared the results to protein in silico predictions on structure and conservation. Additionally, we collected all available clinical information of the families to come to a conclusion concerning their pathogenic potential and facilitate clinical diagnosis in the affected families. We provide evidence that four of the alterations are causative for Lynch syndrome, four are likely neutral and one shows compromised activity which can currently not be classified with respect to its pathogenic potential. The work demonstrates that biochemical testing, corroborated by congruent evolutionary and structural information, can serve to reliably classify uncertain variants when other data are insufficient.Barretos Cancer Hospital was partially funded by FINEPâCTâINFRA, Grant Number: 02/2010, Radium Hospital Foundation (Oslo, Norway), Helse SĂžrâĂst (Norway); Deutsche Forschungsgemeinschaft, Grant Number: PL688/2â1info:eu-repo/semantics/publishedVersio
From colorectal cancer pattern to the characterization of individuals at risk: Picture for genetic research in Latin America
Colorectal cancer (CRC) is one of the most common cancers in Latin America and the Caribbean, with the highest rates reported for Uruguay, Brazil and Argentina. We provide a global snapshot of the CRC patterns, how screening is performed, and compared/contrasted to the genetic profile of Lynch syndrome (LS) in the region. From the literature, we find that only nine (20%) of the Latin America and the Caribbean countries have developed guidelines for early detection of CRC, and also with a low adherence. We describe a genetic profile of LS, including a total of 2,685 suspected families, where confirmed LS ranged from 8% in Uruguay and Argentina to 60% in Peru. Among confirmed LS, path_MLH1 variants were most commonly identified in Peru (82%), Mexico (80%), Chile (60%), and path_MSH2/EPCAM variants were most frequently identified in Colombia (80%) and Argentina (47%). Path_MSH6 and path_PMS2 variants were less common, but they showed important presence in Brazil (15%) and Chile (10%), respectively. Important differences exist at identifying LS families in Latin American countries, where the spectrum of path_MLH1 and path_MSH2 variants are those most frequently identified. Our findings have an impact on the evaluation of the patients and their relatives at risk for LS, derived from the gene affected. Although the awareness of hereditary cancer and genetic testing has improved in the last decade, it is remains deficient, with 39%â80% of the families not being identified for LS among those who actually met both the clinical criteria for LS and showed MMR deficiency.Fil: Vaccaro, Carlos Alberto. Hospital Italiano; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: LĂłpez Kostner, Francisco. No especifĂca;Fil: Adriana, Della Valle. Hospital Fuerzas Armadas; UruguayFil: Inez Palmero, Edenir. Hospital de cĂĄncer de Barretos, FACISB; BrasilFil: Rossi, Benedito Mauro. Hospital Sirio Libanes; BrasilFil: Antelo, Marina. Gobierno de la Ciudad de Buenos Aires. Hospital de GastroenterologĂa "Dr. Carlos B. Udaondo"; Argentina. Universidad Nacional de LanĂșs; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Solano, Angela Rosario. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de Investigaciones BiomĂ©dicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones BiomĂ©dicas; ArgentinaFil: Carraro, Dirce Maria. No especifĂca;Fil: Forones, Nora Manoukian. Universidade Federal de Sao Paulo; BrasilFil: Bohorquez, Mabel. Universidad del Tolima; ColombiaFil: Lino Silva, Leonardo S.. Instituto Nacional de Cancerologia; MĂ©xicoFil: Buleje, Jose. Universidad de San MartĂn de Porres; PerĂșFil: Spirandelli, Florencia. No especifĂca;Fil: Abe Sandes, Kiyoko. Universidade Federal da Bahia; BrasilFil: Nascimento, Ivana. No especifĂca;Fil: Sullcahuaman, Yasser. Universidad Peruana de Ciencias Aplicadas; PerĂș. Instituto de InvestigaciĂłn Genomica; PerĂșFil: Sarroca, Carlos. Hospital Fuerzas Armadas; UruguayFil: Gonzalez, Maria Laura. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de Medicina Traslacional e IngenierĂa BiomĂ©dica - Hospital Italiano. Instituto de Medicina Traslacional e IngenierĂa BiomĂ©dica.- Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional e IngenierĂa BiomĂ©dica; ArgentinaFil: Herrando, Alberto Ignacio. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de Medicina Traslacional e IngenierĂa BiomĂ©dica - Hospital Italiano. Instituto de Medicina Traslacional e IngenierĂa BiomĂ©dica.- Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional e IngenierĂa BiomĂ©dica; ArgentinaFil: Alvarez, Karin. No especifĂca;Fil: Neffa, Florencia. Hospital Fuerzas Armadas; UruguayFil: GalvĂŁo, Henrique Camposreis. Barretos Cancer Hospital; BrasilFil: Esperon, Patricia. Hospital Fuerzas Armadas; UruguayFil: Golubicki, Mariano. Gobierno de la Ciudad de Buenos Aires. Hospital de GastroenterologĂa "Dr. Carlos B. Udaondo"; ArgentinaFil: Cisterna, Daniel. Gobierno de la Ciudad de Buenos Aires. Hospital de GastroenterologĂa "Dr. Carlos B. Udaondo"; ArgentinaFil: Cardoso, Florencia C.. Centro de EducaciĂłn Medica E Invest.clinicas; ArgentinaFil: Tardin Torrezan, Giovana. No especifĂca;Fil: Aguiar Junior, Samuel. No especifĂca;Fil: Aparecida Marques Pimenta, CĂ©lia. Universidade Federal de Sao Paulo; BrasilFil: Nirvana da Cruz Formiga, MarĂa. No especifĂca;Fil: Santos, Erika. Hospital Sirio Libanes; BrasilFil: SĂĄ, Caroline U.. Hospital Sirio Libanes; BrasilFil: Oliveira, Edite P.. Hospital Sirio Libanes; BrasilFil: Fujita, Ricardo. Universidad de San MartĂn de Porres; PerĂșFil: Spirandelli, Enrique. No especifĂca;Fil: Jimenez, Geiner. No especifĂca;Fil: Santa Cruz Guindalini, Rodrigo. Universidade de Sao Paulo; BrasilFil: Gondim Meira Velame de Azevedo, Renata. No especifĂca;Fil: Souza Mario Bueno, Larissa. Universidade Federal da Bahia; BrasilFil: dos Santos Nogueira, Sonia Tereza. No especifĂca;Fil: Piñero, Tamara Alejandra. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de Medicina Traslacional e IngenierĂa BiomĂ©dica - Hospital Italiano. Instituto de Medicina Traslacional e IngenierĂa BiomĂ©dica.- Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional e IngenierĂa BiomĂ©dica; Argentin
A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America
Background: Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants spectrum of patients with suspected LS in Latin America.
Methods: Eleven LS hereditary cancer registries and 34 published LS databases were used to identify unrelated families that fulfilled the Amsterdam II (AMSII) criteria and/or the Bethesda guidelines or suggestive of a dominant colorectal (CRC) inheritance syndrome.
Results: We performed a thorough investigation of 15 countries and identified 6 countries where germline genetic testing for LS is available and 3 countries where tumor testing is used in the LS diagnosis. The spectrum of pathogenic MMR variants included MLH1 up to 54%, MSH2 up to 43%, MSH6 up to 10%, PMS2 up to 3% and EPCAM up to 0.8%. The Latin America MMR spectrum is broad with a total of 220 different variants which 80% were private and 20% were recurrent. Frequent regions included exons 11 of MLH1 (15%), exon 3 and 7 of MSH2 (17 and 15%, respectively), exon 4 of MSH6 (65%), exons 11 and 13 of PMS2 (31% and 23%, respectively). Sixteen international founder variants in MLH1, MSH2 and MSH6 were identified and 41 (19%) variants have not previously been reported, thus representing novel genetic variants in the MMR genes. The AMSII criteria was the most used clinical criteria to identify pathogenic MMR carriers although microsatellite instability, immunohistochemistry and family history are still the primary methods in several countries where no genetic testing for LS is available yet.
Conclusion: The Latin America LS pathogenic MMR variants spectrum included new variants, frequently altered genetic regions and potential founder effects, emphasizing the relevance implementing Lynch syndrome genetic testing and counseling in all of Latin America countries.Radium Hospital Foundation (Oslo, Norway) in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript, Helse SĂžr-Ăst (Norway) in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript, the French Association Recherche contre le Cancer (ARC) in the analysis, and interpretation of data, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (Gefluc) in the analysis, and interpretation of data, the Association Nationale de la Recherche et de la Technologie (ANRT, CIFRE PhD fellowship to H.T.) in the analysis, and interpretation of data and by the OpenHealth Institute in the analysis, and interpretation of data. Barretos Cancer Hospital received financial support by FINEP-CT-INFRA (02/2010)info:eu-repo/semantics/publishedVersio
Microbiota Phenotype Promotes Anastomotic Leakage in a Model of Rats with Ischemic Colon Resection
Anastomotic leakage (AL) is a major cause of morbidity and mortality after colorectal surgery, but the mechanism behind this complication is still not fully understood. Despite the advances in surgical techniques and perioperative care, the complication rates have remained steady. Recently, it has been suggested that colon microbiota may be involved in the development of complications after colorectal surgery. The aim of this study was to evaluate the association of gut microbiota in the development of colorectal AL and their possible virulence strategies to better understand the phenomenon. Using 16S rRNA sequencing of samples collected on the day of surgery and the sixth day following surgery, we analyzed the changes in tissue-associated microbiota at anastomotic sites created in a model of rats with ischemic colon resection. We discovered a trend for lower microbial diversity in the AL group compared to non-leak anastomosis (NLA). There were no differences in relative abundance in the different types of microbial respiration between these groups and the high abundance of the facultative anaerobic Gemella palaticanis is a marker species that stands out as a distinctive feature
Spectrum of MLH1 and MSH2 mutations in Chilean Families with suspected Lynch syndrome
PURPOSE: Lynch syndrome is the most common inherited syndrome of colorectal cancer, caused principally by germline mutations in MLH1 and MSH2. We report our experience with genetic screening in the diagnosis of Lynch syndrome in Chile, a country previously underserved in the capacity to diagnose hereditary colorectal cancer. METHODS: Families from our Familial Colorectal Cancer Registry were selected for this study if they fulfilled either Amsterdam I/II or Bethesda criteria for classification of Lynch syndrome. Analysis of colorectal tumors from probands included a microsatellite instability study and immunohistochemical evaluation for MLH1 and MSH2. Screening of germline mutations was performed by single-strand conformation polymorphism analysis and DNA sequencing. RESULTS: A total of 21 families were evaluated, 14 meeting Amsterdam criteria and 7 meeting Bethesda criteria. Tumors in 20 families (95%) showed microsatellite instability (19 high and 1 low) and 9 of these 20 families (
Tu1727 Inflammatory and Innate Immune Response Activated by Adherent-Invasive Escherichia coli Strains Isolated From Crohn's Disease Patients
Escherichia coli isolates from inflammatory bowel diseases patientssurvive in macrophages and activate NLRP3 inflammasome
ArtĂculo de publicaciĂłn ISICrohnâs disease (CD) is a multifactorial pathology associated with the presence of adherent-invasiveEscherichia coli (AIEC) and NLRP3 polymorphic variants. The presence of intracellular E. coli in otherintestinal pathologies (OIP) and the role of NLRP3-inflammasome in the immune response activated bythese bacteria have not been investigated. In this study, we sought to characterize intracellular strainsisolated from patients with CD, ulcerative colitis (UC) and OIP, and analyze NLRP3-inflammasome rolein the immune response and bactericidal activity induced in macrophages exposed to invasive bacteria.For this, intracellular E. coli isolation from ileal biopsies, using gentamicin-protection assay, revealeda prevalence and CFU/biopsy of E. coli higher in biopsies from CD, UC and OIP patients than in con-trols. To characterize bacterial isolates, pulsed-field gel electrophoresis (PFGE) patterns, virulence genes,serogroup and phylogenetic group were analyzed. We found out that bacteria isolated from a given patientwere closely related and shared virulence factors; however, strains from different patients were geneti-cally heterogeneous. AIEC characteristics in isolated strains, such as invasive and replicative properties,were assessed in epithelial cells and macrophages, respectively. Some strains from CD and UC demon-strated AIEC properties, but not strains from OIP. Furthermore, the role of NLRP3 in pro-inflammatorycytokines production and bacterial elimination was determined in macrophages. E. coli strains inducedIL-1 through NLRP3-dependent mechanism; however, their elimination by macrophages was indepen-dent of NLRP3. Invasiveness of intracellular E. coli strains into the intestinal mucosa and IL-1 productionmay contribute to CD and UC pathogenesis.Funding support from FONDECYT 1120577 (MH), FONDECYT1110260 (R.V.), PI2012-DA015 CLC, PI2010-DA CLC (R.Q.), NationalInstitutes of Health grants AI063331 and AI064748 (G.N.) andMECESUP UCH 0714 and CONICYT fellowships (M.D.L.F.)
Corrigendum to âEscherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasomeâ [Int. J. Med. Microbiol. 304 (3â4) (2014) 384â392]
Increased production of soluble TLR2 by lamina propria mononuclear cells from ulcerative colitis patients
Toll-like receptor 2 (TLR2) is a type I pattern recognition receptor that has been shown to participate in intestinal homeostasis. Its increased expression in the lamina propria has been associated with the pathogenesis in inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Recently, soluble TLR2 (sTLR2) variants have been shown to counteract inflammatory responses driven by the cognate receptor. Despite the evident roles of TLR2 in intestinal immunity, no study has elucidated the production and cellular source of sTLR2 in IBD. Furthermore, an increase in the population of activated macrophages expressing TLR2 that infiltrates the intestine in IBD has been reported. We aimed first to assess the production of the sTLR2 by UC and CD organ culture biopsies and lamina propria mononuclear cells (LPMCs) as well as the levels of sTLR2 in serum, and then characterize the cell population from lamina propria producing the soluble protein.Mucosa explants,